UHS: Short-Term Operational Headwinds but Intact Long-Term Earnings Power Support Buy Rating and $245 Target

TD Cowen analyst Ryan Langston maintained a Buy rating on Universal Health today and set a price target of $245.00.

Ryan Langston has given his Buy rating due to a combination of factors, including only minor downward revisions to near‑term revenue and EBITDA despite recent operational headwinds. While winter storms and higher payer denials are expected to modestly weigh on first‑quarter volumes and nonprofit peers, he views these impacts as temporary and partially mitigated at UHS by a higher‑acuity inpatient mix, Nevada supplemental payments, and tighter cost controls.

He also maintains confidence in the company’s longer‑term earnings power, as reflected in essentially unchanged 2026–2027 adjusted EBITDA forecasts and an intact $245 price target. Langston notes that potential disruptions such as the SYK cyber issue appear limited and largely timing‑related, and he expects UHS to navigate evolving payer and exchange dynamics effectively, supporting an attractive valuation multiple and justifying a continued Buy recommendation.

In another report released on April 13, Guggenheim also maintained a Buy rating on the stock with a $238.00 price target.